, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (&#34; BioVaxys&#34; 或 &#34; 公司&#34;) 宣布，继其于 2025 年 2 月 13 日发布的新闻稿后，其主要监管机构不列颠哥伦比亚省证券委员会（&#34; BCSC&#34;）已接受公司的申请，并已授予管理停止交易令（&#34; MCTO&#34;），根据国家政策 12-203 – 管理停止交易令（&#34; NP 12-203&#34;).
如之前所述，公司申请了 MCTO，因为预计其截至 2024 年 10 月 31 日的审计年度财务报表、相关管理讨论与分析以及其 52-109FV1 表格的首席执行官和首席财务官年度认证（统称为&#34; 所需文件&#34;）的提交将会有短期延迟。根据国家工具 51-102 - 持续披露义务，所需文件必须在 2025 年 2 月 28 日之前提交。
虽然正在尽一切努力尽快提交所需文件，但导致延迟的因素之一是最近于 2024 年 2 月 16 日完成的对前 IMV Inc.所有知识产权、免疫治疗平台技术和临床阶段资产的收购。此次收购涉及 120 项专利，审计师完成对这些专利的审查和评估所需的时间比预期更长。公司预计其审计师 Dale Matheson Carr-Hilton LaBonte LLP 将在 2025 年 3 月 30 日之前完成审计，所需文件将在此之后尽快完成。
在 MCTO 生效期间，公众仍然可以自由交易公司的上市普通股。然而，MCTO 将禁止公司的首席执行官和首席财务官在所需文件未提交期间交易公司的证券。此外，公司在所需文件提交之前，将被禁止直接或间接向公司内部人士或员工发行或收购证券，直到所需文件提交并满足所有持续披露要求，且 MCTO 被撤销。
公司确认将遵守 NP 12-203 下的替代信息指引，通过发布双周的违约状态报告（以新闻稿形式），直到所需文件提交并满足所有持续披露要求，且 MCTO 被撤销。公司还确认，截至本新闻稿发布之日，未对其进行破产程序，并且没有其他关于公司事务的重大信息未被普遍披露。
关于 BioVaxys Technology Corp.
BioVaxys Technology Corp.（www.biovaxys.com）是一家注册于加拿大不列颠哥伦比亚省的生物制药公司，致力于通过基于 DPX™免疫教育技术平台和 HapTenix© '新抗原'肿瘤细胞构建平台的创新免疫疗法改善患者生活，治疗癌症、传染病、抗原脱敏及其他免疫学领域。公司的临床阶段管道包括 maveropepimut-S，目前正在进行针对晚期复发难治性弥漫大 B 细胞淋巴瘤（DLBCL）和铂耐药卵巢癌的二期临床开发，以及 BVX-0918，这是一种个性化免疫治疗疫苗，使用其专有的 HapTenix© '新抗原'肿瘤细胞构建平台，预计将在西班牙进入一期临床试验，治疗难治性晚期卵巢癌。
公司还利用其肿瘤免疫学知识和在个性化免疫治疗疫苗接种后创建的独特 T 淋巴细胞库及其他数据集，利用预测算法和其他技术识别新的可靶向肿瘤抗原。
BioVaxys 的普通股在加拿大证券交易所上市，股票代码为&#34;BIOV&#34;，并在法兰克福证券交易所（FRA: 5LB）和美国 OTC 市场（OTCQB 市场）交易。有关更多信息，请访问 www.biovaxys.com，并在 X 和 LinkedIn 上与我们联系。
代表董事会
签名 &#34; James Passin&#34;
James Passin，首席执行官
电话：+1 740 358 0555
关于前瞻性信息的警示声明
本新闻稿包含某些&#34;前瞻性信息&#34;和&#34;前瞻性声明&#34;（统称为&#34; 前瞻性声明&#34;），符合适用证券立法的定义。除历史事实外，本文中包含的所有声明，包括但不限于与所需文件在 2025 年 3 月 30 日之前提交以及公司遵守 NP 12-203 所述替代信息指引的能力相关的声明，均为前瞻性声明。前瞻性声明通常但不总是通过诸如&#34;预计&#34;、&#34;预期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;估计&#34;、&#34;潜在&#34;、&#34;可能&#34;等词语或声明事件、条件或结果&#34;将&#34;、&#34;可能&#34;、&#34;可以&#34;或&#34;应该&#34;发生或实现来识别。不能保证这些声明将被证明是准确的，实际结果和未来事件可能与这些前瞻性声明中表达或暗示的结果有实质性差异。
这些前瞻性声明反映了声明发布时的信念、观点和预测，并基于多个假设和估计，主要假设是 BioVaxys 将在疫苗的开发和测试中取得成功，尽管 BioVaxys 认为这些假设是合理的，但本质上仍然受到重大商业、经济、竞争、政治和社会不确定性及偶发事件的影响。许多已知和未知的因素可能导致实际结果、表现或成就与这些前瞻性声明所表达或暗示的结果、表现或成就存在重大差异，相关方已基于或与这些因素相关的许多假设和估计作出判断。这些因素包括但不限于，公司可能无法在 2025 年 3 月 30 日之前提交所需文件的风险。BioVaxys 不承担任何更新前瞻性声明的义务，包括信念、观点、预测或其他因素的变化，除非适用的证券法律要求。
加拿大证券交易所未审查、批准或否决本新闻稿的内容，并不对本稿的充分性或准确性承担责任。
Logo: https://mma.prnewswire.com/media/2415135/5196269/BioVaxys_Technology_Corp_Logo.jpg
来源：BioVaxys Technology Corp.
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzAzJk5ld3NJdGVtSWQ9TE4zMjM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMDMxODE5UFJfTkVXU19VU1BSX19fX19MTjMyMzQ4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzAzJk5ld3NJdGVtSWQ9TE4zMjM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMDMxODE5UFJfTkVXU19VU1BSX19fX19MTjMyMzQ4"/>

IMVIF

BioVaxys Technology Corp. 已被不列颠哥伦比亚省证券委员会授予管理停止交易令（MCTO），原因是未能按时提交截至 2024 年 10 月 31 日的经审计年度财务报表。延迟的原因是最近从 IMV Inc. 收购了知识产权和临床资产。公司预计将在 2025 年 3 月 30 日前完成所需的文件提交。在 MCTO 生效期间，首席执行官和首席财务官被禁止交易公司的证券，但公众仍可以继续交易公司的股票

, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (&#34; BioVaxys&#34; or &#34; Company&#34;) announces that, further to its news release dated February 13, 2025, its principal regulator, the British Columbia Securities Commission (the &#34; BCSC&#34;), has accepted the Company's application for, and has granted, a management cease trade order (the &#34; MCTO&#34;) under National Policy 12-203 – Management Cease Trade Orders (&#34; NP 12-203&#34;).
<div class="lb-trans">, /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (&#34; BioVaxys&#34; 或 &#34; 公司&#34;) 宣布，继其于 2025 年 2 月 13 日发布的新闻稿后，其主要监管机构不列颠哥伦比亚省证券委员会（&#34; BCSC&#34;）已接受公司的申请，并已授予管理停止交易令（&#34; MCTO&#34;），根据国家政策 12-203 – 管理停止交易令（&#34; NP 12-203&#34;).
</div>As previously announced, the Company applied for the MCTO as it anticipated a short-term delay in the filing of its audited annual financial statements for the year ended October 31, 2024, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the &#34; Required Filings&#34;). Under National Instrument 51-102 - Continuous Disclosure Obligations, the Required Filings were required to be made not later than February 28, 2025.
<div class="lb-trans">如之前所述，公司申请了 MCTO，因为预计其截至 2024 年 10 月 31 日的审计年度财务报表、相关管理讨论与分析以及其 52-109FV1 表格的首席执行官和首席财务官年度认证（统称为&#34; 所需文件&#34;）的提交将会有短期延迟。根据国家工具 51-102 - 持续披露义务，所需文件必须在 2025 年 2 月 28 日之前提交。
</div>While every effort is being made to make the Required Filings as soon as possible, one of the factors contributing to the delay is the recent acquisition of all intellectual property, immunotherapeutics platform Technology, and clinical stage assets of the former IMV Inc. completed on February 16, 2024. The purchase involved the acquisition of 120 patents, and it is taking longer than expected for the auditor to complete its review and valuation of the patents. The Company expects that its auditor, Dale Matheson Carr-Hilton LaBonte LLP, will be in a position to complete the audit by March 30, 2025, ‎with the Required Filings to be completed as soon as possible ‎thereafter.‎
<div class="lb-trans">虽然正在尽一切努力尽快提交所需文件，但导致延迟的因素之一是最近于 2024 年 2 月 16 日完成的对前 IMV Inc.所有知识产权、免疫治疗平台技术和临床阶段资产的收购。此次收购涉及 120 项专利，审计师完成对这些专利的审查和评估所需的时间比预期更长。公司预计其审计师 Dale Matheson Carr-Hilton LaBonte LLP 将在 2025 年 3 月 30 日之前完成审计，所需文件将在此之后尽快完成。
</div>While the MCTO is in effect, the general investing public will continue to be able to trade freely the Company's listed common shares. However, the MCTO will prohibit the Company's Chief Executive Officer and Chief Financial Officer from trading securities of the Company for so long as the Required Filings are not filed. Additionally, the Company will be prohibited from directly or indirectly issuing or acquiring securities from insiders or employees of the Company until such time as the Required Filings have been made and all continuous disclosure requirements have been met by the Company, and the MCTO has been revoked.
<div class="lb-trans">在 MCTO 生效期间，公众仍然可以自由交易公司的上市普通股。然而，MCTO 将禁止公司的首席执行官和首席财务官在所需文件未提交期间交易公司的证券。此外，公司在所需文件提交之前，将被禁止直接或间接向公司内部人士或员工发行或收购证券，直到所需文件提交并满足所有持续披露要求，且 MCTO 被撤销。
</div>The Company confirms that it will comply with the alternative information guidelines set out under NP 12-203 by issuing bi-weekly default status reports, in the form of news releases, until such time as the Required Filings have been made and all continuous disclosure requirements have been met by the Company, and the MCTO has been revoked. The Company also confirms as of the date of this news release that there is no insolvency proceeding against it and there is no other material information concerning the affairs of the Company that has not been generally disclosed.
<div class="lb-trans">公司确认将遵守 NP 12-203 下的替代信息指引，通过发布双周的违约状态报告（以新闻稿形式），直到所需文件提交并满足所有持续披露要求，且 MCTO 被撤销。公司还确认，截至本新闻稿发布之日，未对其进行破产程序，并且没有其他关于公司事务的重大信息未被普遍披露。
</div>About BioVaxys Technology Corp.
<div class="lb-trans">关于 BioVaxys Technology Corp.
</div>BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
<div class="lb-trans">BioVaxys Technology Corp.（www.biovaxys.com）是一家注册于加拿大不列颠哥伦比亚省的生物制药公司，致力于通过基于 DPX™免疫教育技术平台和 HapTenix© '新抗原'肿瘤细胞构建平台的创新免疫疗法改善患者生活，治疗癌症、传染病、抗原脱敏及其他免疫学领域。公司的临床阶段管道包括 maveropepimut-S，目前正在进行针对晚期复发难治性弥漫大 B 细胞淋巴瘤（DLBCL）和铂耐药卵巢癌的二期临床开发，以及 BVX-0918，这是一种个性化免疫治疗疫苗，使用其专有的 HapTenix© '新抗原'肿瘤细胞构建平台，预计将在西班牙进入一期临床试验，治疗难治性晚期卵巢癌。
</div>The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes &amp; other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.
<div class="lb-trans">公司还利用其肿瘤免疫学知识和在个性化免疫治疗疫苗接种后创建的独特 T 淋巴细胞库及其他数据集，利用预测算法和其他技术识别新的可靶向肿瘤抗原。
</div>BioVaxys common shares are listed on the Canadian Securities Exchange under the stock symbol &#34;BIOV&#34; and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
<div class="lb-trans">BioVaxys 的普通股在加拿大证券交易所上市，股票代码为&#34;BIOV&#34;，并在法兰克福证券交易所（FRA: 5LB）和美国 OTC 市场（OTCQB 市场）交易。有关更多信息，请访问 www.biovaxys.com，并在 X 和 LinkedIn 上与我们联系。
</div>ON BEHALF OF THE BOARD
<div class="lb-trans">代表董事会
</div>Signed &#34; James Passin&#34;
<div class="lb-trans">签名 &#34; James Passin&#34;
</div>James Passin, Chief Executive Officer
<div class="lb-trans">James Passin，首席执行官
</div>Phone: +1 740 358 0555
<div class="lb-trans">电话：+1 740 358 0555
</div>Cautionary Statements Regarding Forward Looking Information
<div class="lb-trans">关于前瞻性信息的警示声明
</div>This news release includes certain &#34;forward-looking information&#34; and &#34;forward-looking statements&#34; (collectively &#34; forward-looking statements&#34;) within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the filing of the Required Filings by March 30, 2025 and the Company's ability to comply with the provision of the alternative information guidelines described by NP 12-203, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as &#34;expects&#34;, &#34;anticipates&#34;, &#34;believes&#34;, &#34;intends&#34;, &#34;estimates&#34;, &#34;potential&#34;, &#34;possible&#34;, and similar expressions, or statements that events, conditions, or results &#34;will&#34;, &#34;may&#34;, &#34;could&#34;, or &#34;should&#34; occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
<div class="lb-trans">本新闻稿包含某些&#34;前瞻性信息&#34;和&#34;前瞻性声明&#34;（统称为&#34; 前瞻性声明&#34;），符合适用证券立法的定义。除历史事实外，本文中包含的所有声明，包括但不限于与所需文件在 2025 年 3 月 30 日之前提交以及公司遵守 NP 12-203 所述替代信息指引的能力相关的声明，均为前瞻性声明。前瞻性声明通常但不总是通过诸如&#34;预计&#34;、&#34;预期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;估计&#34;、&#34;潜在&#34;、&#34;可能&#34;等词语或声明事件、条件或结果&#34;将&#34;、&#34;可能&#34;、&#34;可以&#34;或&#34;应该&#34;发生或实现来识别。不能保证这些声明将被证明是准确的，实际结果和未来事件可能与这些前瞻性声明中表达或暗示的结果有实质性差异。
</div>These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the risk that the Company may not be able to file the Required Filings by March 30, 2025. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.
<div class="lb-trans">这些前瞻性声明反映了声明发布时的信念、观点和预测，并基于多个假设和估计，主要假设是 BioVaxys 将在疫苗的开发和测试中取得成功，尽管 BioVaxys 认为这些假设是合理的，但本质上仍然受到重大商业、经济、竞争、政治和社会不确定性及偶发事件的影响。许多已知和未知的因素可能导致实际结果、表现或成就与这些前瞻性声明所表达或暗示的结果、表现或成就存在重大差异，相关方已基于或与这些因素相关的许多假设和估计作出判断。这些因素包括但不限于，公司可能无法在 2025 年 3 月 30 日之前提交所需文件的风险。BioVaxys 不承担任何更新前瞻性声明的义务，包括信念、观点、预测或其他因素的变化，除非适用的证券法律要求。
</div>The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this press release and does not accept responsibility for the adequacy or accuracy of this release.
<div class="lb-trans">加拿大证券交易所未审查、批准或否决本新闻稿的内容，并不对本稿的充分性或准确性承担责任。
</div>Logo: https://mma.prnewswire.com/media/2415135/5196269/BioVaxys_Technology_Corp_Logo.jpg
<div class="lb-trans">Logo: https://mma.prnewswire.com/media/2415135/5196269/BioVaxys_Technology_Corp_Logo.jpg
</div>SOURCE BioVaxys Technology Corp.
<div class="lb-trans">来源：BioVaxys Technology Corp.
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMzAzJk5ld3NJdGVtSWQ9TE4zMjM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNTAzMDMxODE5UFJfTkVXU19VU1BSX19fX19MTjMyMzQ4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN32348&amp;Transmission_Id=202503031819PR_NEWS_USPR_____LN32348&amp;DateId=20250303"/>

BioVaxys Technology Corp. 获得管理层停止交易令